Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, ...

GT Medical Technologies, announced that it has raised $37 million in Series D financing round. The financing round was led ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Monday saw the release of JMP Securities' latest industry overview for the biotechnology sector, which highlighted key events from January 2025. The report noted a modest resurgence in the sector, ...

Digital health firms in the city raised $4 billion in 2024, up 60% from the previous year, according to a report released ...

Cystic-fibrosis-focused Sionna Therapeutics made its public debut this week, with an upsized public offering. Meanwhile, Titan America had a ...

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

IRVINE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the closing of ...

Metsera said this capability could support monthly dosing, offering a less burdensome dosing ... Two other life science companies went public this past week. Here’s a look at those IPOs: Maze ...

Stay updated on the latest financial news and upcoming IPOs/SPACs with this article covering Titan America, Smithfield Foods, ...

Over the last year, Metsera Inc share price has been traded in a range of 4.38, hitting a high of 30.00, and a low of 25.62. Metsera Inc is listed on the CBOE trading with ticker code MTSR.US.